Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - ayvakyt
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mpf40cac7981e52d03bbfe471a7f88b25f
identifier: http://ema.europa.eu/identifier
/EU/1/20/1473/004
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: AYVAKYT 25 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-f40cac7981e52d03bbfe471a7f88b25f
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/20/1473/004
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - ayvakyt
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
What AYVAKYT is AYVAKYT is a medicine containing the active substance avapritinib.
What AYVAKYT is used for AYVAKYT is used in adults to treat aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM-AHN), or mast cell leukaemia (MCL), after at least one systemic therapy. These are disorders in which the body produces too many mast cells, a type of white blood cell. Symptoms are caused when too many mast cells enter various organs of your body, such as the liver, bone marrow or spleen. These mast cells also release substances such as histamine which cause various general symptoms that you may be experiencing as well as damage to involved organs. ASM, SM-AHN and MCL are collectively referred to as advanced systemic mastocytosis (AdvSM).
AYVAKYT is also used for the treatment of adults with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment. This is a disorder in which your body has many abnormal mast cells. Mast cells are the white blood cells responsible for allergic reactions. These cells may be in any tissue in your body but are often found in your skin, your intestines and your bone marrow. These abnormal mast cells can cause symptoms such as severe allergic reactions, diarrhoea, rash and difficulty thinking.
How AYVAKYT works AYVAKYT stops the activity of a group of proteins in the body called kinases. Mast cells in patients with AdvSM and ISM usually have changes (mutations) in the genes involved in making specific kinases associated with the growth and spread of these cells.
If you have any questions about how AYVAKYT works or why this medicine has been prescribed for you, please ask your doctor.
Do not take AYVAKYT:
Warnings and precautions
Talk to your doctor or pharmacist before taking AYVAKYT:
Take special care with this medicine:
While you are taking avapritinib, your doctor will ask you to have regular blood tests and weigh you regularly if you have AdvSM.
For more information see section 4. Children and adolescents
AYVAKYT has not been studied in children and adolescents under age 18. Do not give this medicine to children or adolescents under the age of 18 years.
Other medicines and AYVAKYT Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. AYVAKYT may affect the way other medicines work, and certain other medicines may affect how this medicine works.
Tell your doctor or pharmacist before taking AYVAKYT if you are taking any of the following medicines:
The following medicines can increase the effects of avapritinib and may increase its side effects:
The following medicines can reduce the effects of avapritinib:
This medicine may affect how well the following medicines work or increase their side effects:
Ask your doctor or pharmacist for advice before taking any medicine.
AYVAKYT with food and drink You should not drink grapefruit juice or eat grapefruit while on treatment with AYVAKYT.
Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Pregnancy This medicine is not recommended for use during pregnancy unless clearly necessary. Avoid becoming pregnant while being treated with this medicine as it may harm your unborn baby. Your doctor will discuss with you the potential risks of taking AYVAKYT during pregnancy.
Your doctor may check if you are pregnant before you start treatment with this medicine.
Women who are able to become pregnant should use effective contraception during treatment and for at least 6 weeks after completion of treatment. Males with female partners who are able to become pregnant should use effective contraception during treatment and for at least 2 weeks after completion of treatment. Talk to your doctor about effective contraception methods that may be right for you.
Breast-feeding Tell your doctor if you are breast-feeding or planning to breast-feed. It is not known if AYVAKYT passes into breast milk. You should not breast-feed during treatment with this medicine and for at least 2 weeks following the last dose. Talk to your doctor about the best way to feed your baby during this time.
Fertility AYVAKYT may cause fertility problems in males and females. Talk to your doctor if this is a concern for you.
Driving and using machines AYVAKYT may cause symptoms that affect your ability to concentrate and react (see section 4). Therefore, AYVAKYT may influence the ability to drive and use machines. Take special care when driving a car or operating machines if you experience these side effects.
AYVAKYT contains sodium This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially sodium- free .
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
Which strength of AYVAKYT to use
The recommended dose of AYVAKYT will depend on your illness see below.
AYVAKYT is available in different strength tablets. The strengths are 25 mg, 50 mg, 100 mg, 200 mg and 300 mg. Your doctor will advise you about the strength and number of tablets you should take:
Treatment of AdvSM The recommended dose is 200 mg by mouth once daily.
Treatment of ISM The recommended dose is 25 mg by mouth once daily.
If you have liver problems, your doctor may start you on a lower dose of AYVAKYT.
If you get side effects, your doctor may change your dose, temporarily stop, or permanently stop treatment. Do not change your dose or stop taking AYVAKYT unless your doctor tells you to.
Swallow the AYVAKYT tablet(s) whole with a glass of water, on an empty stomach. Do not eat for at least 2 hours before and at least 1 hour after taking AYVAKYT.
If you vomit after taking a dose of AYVAKYT, do not take an extra dose. Take your next dose at your scheduled time.
If you take more AYVAKYT than you should If you have accidentally taken too many tablets, talk to your doctor straight away. You may require medical attention.
If you forget to take AYVAKYT If you miss a dose of AYVAKYT, take it as soon as you remember unless your next scheduled dose is due within 8 hours. Take the next dose at your regular time.
Do not take two doses within 8 hours to make up for a forgotten dose.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Most serious side effects in patients with AdvSM Some side effects may be serious. Tell your doctor straight away if you get any of the following (see also section 2.):
Other side effects in patients with AdvSM may include Very common (may affect more than 1 in 10 people):
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Side effects in patients with ISM may include Very common (may affect more than 1 in 10 people):
Common (may affect up to 1 in 10 people):
trouble falling asleep (insomnia)
flushing
red or itchy skin
face swelling
blood test showing effect on the bone (blood alkaline phosphatase increased)
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the bottle label and outer carton after EXP . The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Do not use this medicine if you notice that the bottle is damaged or shows signs of tampering.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What AYVAKYT contains
The active substance is avapritinib. Each film-coated tablet contains 25 mg avapritinib.
The other ingredients are:
The tablet core contains: microcrystalline cellulose, copovidone, croscarmellose sodium and magnesium stearate (see section 2 AYVAKYT contains sodium ).
The tablet coating contains: talc, macrogol 3350, poly(vinyl alcohol), and titanium dioxide (E171).
What AYVAKYT looks like and contents of the pack AYVAKYT 25 mg film-coated tablets are round, white tablets of 5 mm diameter, debossed with BLU on one side and 25 on the other.
AYVAKYT is supplied in a bottle containing 30 film-coated tablets. Each carton contains one bottle.
Keep the desiccant canister in the bottle.
Marketing Authorisation Holder and Manufacturer Blueprint Medicines (Netherlands) B.V. Gustav Mahlerplein 2 1082 MA Amsterdam Netherlands
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Belgi /Belgique/Belgien, , esk
republika, Danmark, Deutschland, Eesti, Espa a, France, Hrvatska, Ireland, sland, ,
Swixx Biopharma S.M.S.A.
: +30 214 444 9Italia, Latvija, Lietuva, Luxembourg/Luxemburg, Magyarorsz g, Malta, Nederland, Norge, sterreich, Polska, Portugal, Rom nia, Slovenija, Slovensk
republika, Suomi/Finland, Sverige, United Kingdom (Northern Ireland) Blueprint Medicines (Netherlands) B.V., NL Tel/ T l/ Te / Tlf/ S mi/ Puh: +31 85 064 4e-mail: MedinfoEurope@blueprintmedicines.com
This leaflet was last revised in
This medicine has been given conditional approval .
This means that there is more evidence to come about this medicine. The European Medicines Agency will review new information on this medicine at least every year and this leaflet will be updated as necessary.
Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-f40cac7981e52d03bbfe471a7f88b25f
Resource Composition:
Generated Narrative: Composition composition-en-f40cac7981e52d03bbfe471a7f88b25f
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/20/1473/004status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - ayvakyt
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mpf40cac7981e52d03bbfe471a7f88b25f
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mpf40cac7981e52d03bbfe471a7f88b25f
identifier:
http://ema.europa.eu/identifier
/EU/1/20/1473/004type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: AYVAKYT 25 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en